Committed to Improving
 Outcomes in Cancer

Who We Are

Leapfrog Bio is an emerging oncology therapeutics company leveraging our Precision PGx Platform to identify and develop novel targeted therapeutics.  Our approach utilizes synthetic lethality and pharmacogenomic screening to reveal treatment options for patients suffering from cancer due to “loss of function” mutations.  We are passionate and aligned with our team, board and investors to achieve this important goal.

Management

University of Florida BS Chemistry, UC Berkeley Haas School of Business MBA, Merck, Genentech, Connectics Corporation, Topica Pharmaceuticals and BlackThorn Therapeutics

Greg Vontz
CEO

University of Toronto PhD Molecular Genetics, Adjunct Professor Biology Queen’s University, Stanford, Celgene, Merck, Bristol-Myers Squibb

Tomas Babak, PhD
Founder and CSO

Princeton University, AB Politics; University of Chicago JD and MBA; Morgan Stanley & Company, Wilson Sonsini Goodrich & Rosati, Xalud Therapeutics, Aimmune Therapeutics, BioElectron Technology Corporation.

Peter Heinecke
CBO and GC

M.D. and Ph.D. from The Johns Hopkins University School of Medicine, Howard Hughes Research Fellow and Visiting Scientist at the National Cancer Institute and the National Human Genome Research Institute, Amgen, Medimmune, AstraZeneca, Five Prime

Robert Sikorski, MD, PhD
CMO

Board of Directors

Greg Vontz
CEO and Director
Tomas Babak, PhD
CSO and Director
Mike Goguen
Chairman of the Board
J Seth Strattan, PhD
Director
Richard Miller, MD
Independent Director

Investors